PHC LiCellMo Wins 2024 Innovation Award from The Analytical Scientist
PHC Corporation’s Biomedical Division (Headquarters: Chiyoda-ku, Tokyo, Japan; President: Nobuaki Nakamura) has been awarded the 2024 Innovation Award by The Analytical Scientist for its live-cell metabolic analyzer, LiCellMo™. Launched in Japan in September and in select regions, including the US,…
Upbound to Acquire Brigit for Up to $460 Million
Upbound Group, Inc. (NASDAQ: UPBD), a leader in accessible and inclusive financial products powered by technology and data, has announced a definitive agreement to acquire Brigit, a top financial health technology company, for up to $460 million. The deal will…
Corcept Announces Positive CATALYST Trial Results
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company focused on developing medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating cortisol, announced today that the primary endpoint was met in the treatment phase of CATALYST. This randomized,…
Parse Biosciences Launches Mouse BCR for Antibody Discovery
Parse Biosciences, a leader in scalable single-cell sequencing solutions, today announced the expansion of its Evercode BCR™ product line to support mouse applications. The new kits allow researchers to profile the mouse BCR repertoire alongside whole transcriptome data for millions…
Lyra Forecast: Rising Mental Health Claims for Youth and Severe Needs
Lyra Health, a leader in Workforce Mental Health solutions for employers, today shared early insights from its 2025 Workforce Mental Health Trends Forecast. The fifth annual study found that 81% of benefits leaders are increasingly worried about the rising levels…
Repare Therapeutics Reports Positive Results from MYTHIC Phase 1 Trial
Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced positive data from its MYTHIC Phase 1 gynecologic expansion clinical trial. The trial evaluated the combination of lunresertib and camonsertib (Lunre+Camo) at the recommended Phase 2 dose (RP2D)…
NanoVibronix Secures $12M Commitment for PainShield with Distribution Agreement Extension
NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company specializing in surface acoustic wave (SAW) technology, has announced the renewal of its exclusive distribution agreement with Ultra Pain Products, Inc. (UPPI) for the distribution of the PainShield device. The five-year extension…
SamanTree Medical Reports 67% Reduction in Reoperation Rates for Breast-Conserving Surgery at 2024 SABCS
SamanTree Medical, a leader in oncologic surgical imaging innovation, announced promising results from the SHIELD study, to be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) on Dec. 12. The findings reveal that the Histolog® Scanner, a confocal…
NeoGenomics Study Highlights ctDNA as a Predictive Tool for High-Risk Melanoma
NeoGenomics, Inc. (NASDAQ: NEO), a leader in oncology testing services, has announced the publication of a new study in ESMO Open. The study highlights the potential of circulating tumor DNA (ctDNA) as a tool for monitoring molecular residual disease (MRD)…
Syncell Announces $15 Million Series A to Boost Global Growth of Protein Purification and Spatial Proteomics Tech
Syncell, a leader in advanced subcellular protein purification and spatial proteomics analysis, has successfully closed a $15 million Series A funding round, bringing its total funding to $30 million. The capital will be used to drive the global commercialization and…
Mindset Medical Gets FDA Clearance for Contactless Pulse Rate Device
Mindset Medical, Inc., a digital health company, today announced that it has received FDA 510(k) clearance for its contactless pulse rate measurement device, the Informed Vital Core (IVC) App. This marks the company’s first FDA clearance and is a major…
RevBio Gets FDA Approval to Expand Trial and CMS Reimbursement for Regenerative Bone Adhesive
RevBio, Inc. announced that it has received FDA approval to expand its ongoing clinical trial to use TETRANITE®, its bone adhesive biomaterial, for immediate cranial flap fixation. Additionally, the company has secured reimbursement coverage from the Centers for Medicare and…